Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Required: KRAS G12C mutation

KRASG12C mutation

Required: PD-L1 (CD274) TPS ≥1% (TPS ≥1%)

PD-L1 TPS ≥1%

Required: PD-L1 (CD274) TPS <50% (TPS <50%)

PD-L1 TPS < 50%

Must have received: platinum-based chemotherapy (pembrolizumab) — induction

previously completed 4 cycles of standard-of-care platinum based induction chemotherapy with pembrolizumab AND experienced stable disease, partial response, or complete response per investigator's assessment after 4 cycles OR if patients received <4 cycles of a platinum-based induction, was stopped early due to intolerable toxicity

Cannot have received: KRAS inhibitor

Any prior therapy targeting KRASG12C mutation in any setting

Cannot have received: systemic therapy

Exception: adjuvant or neoadjuvant therapy allowed if last dose >1 year prior to first dose of study treatment

Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy (note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was >1 year prior to first dose of study treatment)

Cannot have received: maintenance therapy (pembrolizumab, pemetrexed)

received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following completion of 4-6 cycles of a platinum-based regimen administered in the first-line setting